Novartis AG Common Stock (NVS)

Novartis (NYSE:NVS) said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite continued pressure from U.S. generic erosion tied to Entresto. Chief Executive Officer Vas Narasimhan

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN.

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease...

According to a new report from Intel Market Research, the global Nitrogen-Containing Bisphosphonate Drugs Market was valued at USD 3.65 billion in 2024 and

Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?

Not every international ETF is a can't-miss investment opportunity.

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

When buying international dividend stocks, diversification is likely the best bet.

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs. The acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.

Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

The best AI stocks might be in totally different industries, companies, and countries.

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns.

After decades managing global women's health lines at Novartis and CooperSurgical, Core Restore Centers (986-267-3737) founder Ann Peets announces the availability of a non-invasive, FDA-cleared treatment for bladder leakage—avoiding ineffective medications and unapproved devices.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and…